{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T04:22:39Z","timestamp":1793852559262,"version":"4.6.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T00:00:00Z","timestamp":1698624000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["848041001"],"award-info":[{"award-number":["848041001"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Crit Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The role of haloperidol as treatment for ICU delirium and related symptoms remains controversial despite two recent large controlled trials evaluating its efficacy and safety. We sought to determine whether haloperidol when compared to placebo in critically ill adults with delirium reduces days with delirium and coma and improves delirium-related sequelae.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>This multi-center double-blind, placebo-controlled randomized trial at eight mixed medical-surgical Dutch ICUs included critically ill adults with delirium (Intensive Care Delirium Screening Checklist\u2009\u2265\u20094 or a positive Confusion Assessment Method for the ICU) admitted between February 2018 and January 2020. Patients were randomized to intravenous haloperidol 2.5\u00a0mg or placebo every 8\u00a0h, titrated up to 5\u00a0mg every 8\u00a0h if delirium persisted until ICU discharge or up to 14\u00a0days. The primary outcome was ICU delirium- and coma-free days (DCFDs) within 14\u00a0days after randomization. Predefined secondary outcomes included the protocolized use of sedatives for agitation and related behaviors, patient-initiated extubation and invasive device removal, adverse drug associated events, mechanical ventilation, ICU length of stay, 28-day mortality, and long-term outcomes up to 1-year after randomization.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The trial was terminated prematurely for primary endpoint futility on DSMB advice after enrolment of 132 (65 haloperidol; 67 placebo) patients [mean age 64 (15) years, APACHE IV score 73.1 (33.9), male 68%]. Haloperidol did not increase DCFDs (adjusted RR 0.98 [95% CI 0.73\u20131.31], <jats:italic>p<\/jats:italic>\u2009=\u20090.87). Patients treated with haloperidol (vs. placebo) were less likely to receive benzodiazepines (adjusted OR 0.41 [95% CI 0.18\u20130.89], <jats:italic>p<\/jats:italic>\u2009=\u20090.02). Effect measures of other secondary outcomes related to agitation (use of open label haloperidol [OR 0.43 (95% CI 0.12\u20131.56)] and other antipsychotics [OR 0.63 (95% CI 0.29\u20131.32)], self-extubation or invasive device removal [OR 0.70 (95% CI 0.22\u20132.18)]) appeared consistently more favorable with haloperidol, but the confidence interval also included harm. Adverse drug events were not different. Long-term secondary outcomes (e.g., ICU recall and quality of life) warrant further study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Haloperidol does not reduce delirium in critically ill delirious adults. However, it may reduce rescue medication requirements and agitation-related events in delirious ICU patients warranting further evaluation.<\/jats:p>\n                <jats:p><jats:italic>Trial registration<\/jats:italic>: ClinicalTrials.gov (#NCT03628391), October 9, 2017.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13054-023-04692-3","type":"journal-article","created":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:03:07Z","timestamp":1698681787000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":48,"title":["Efficacy of haloperidol to decrease the burden of delirium in adult critically ill patients: the EuRIDICE randomized clinical trial"],"prefix":"10.1186","volume":"27","clinical-trial-number":[{"clinical-trial-number":"nct03628391","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Lisa","family":"Smit","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen J. C.","family":"Slooter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John W.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zoran","family":"Trogrlic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole G. M.","family":"Hunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert Jan","family":"Osse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huibert H.","family":"Ponssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjen J. B. W.","family":"Brouwers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette F.","family":"Schoonderbeek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koen S.","family":"Simons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"van den Boogaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith A.","family":"Lens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk P.","family":"Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik A. M. P. J.","family":"Gommers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim J. R.","family":"Rietdijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathieu","family":"van der Jagt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the EuRIDICE study group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,30]]},"reference":[{"issue":"1","key":"4692_CR1","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1038\/s41572-020-00223-4","volume":"6","author":"JE Wilson","year":"2020","unstructured":"Wilson JE, Mart MF, Cunningham C, Shehabi Y, Girard TD, MacLullich AMJ, Slooter AJC, Ely EW. Delirium. Nat Rev Dis Prim. 2020;6(1):90.","journal-title":"Nat Rev Dis Prim"},{"issue":"2","key":"4692_CR2","first-page":"185","volume":"370","author":"PP Pandharipande","year":"2014","unstructured":"Pandharipande PP, Girard TD, Ely EW. Long-term cognitive impairment after critical illness. N Engl J Med. 2014;370(2):185\u20136.","journal-title":"N Engl J Med"},{"issue":"4","key":"4692_CR3","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1097\/01.CCM.0000119429.16055.92","volume":"32","author":"EB Milbrandt","year":"2004","unstructured":"Milbrandt EB, Deppen S, Harrison PL, Shintani AK, Speroff T, Stiles RA, Truman B, Bernard GR, Dittus RS, Ely EW. Costs associated with delirium in mechanically ventilated patients. Crit Care Med. 2004;32(4):955\u201362.","journal-title":"Crit Care Med"},{"issue":"12","key":"4692_CR4","doi-asserted-by":"publisher","first-page":"1892","DOI":"10.1007\/s00134-001-1132-2","volume":"27","author":"EW Ely","year":"2001","unstructured":"Ely EW, Gautam S, Margolin R, Francis J, May L, Speroff T, Truman B, Dittus R, Bernard R, Inouye SK. The impact of delirium in the intensive care unit on hospital length of stay. Intensive Care Med. 2001;27(12):1892\u2013900.","journal-title":"Intensive Care Med"},{"issue":"11","key":"4692_CR5","doi-asserted-by":"publisher","first-page":"e1111","DOI":"10.1097\/CCM.0000000000002640","volume":"45","author":"A Morandi","year":"2017","unstructured":"Morandi A, Piva S, Ely EW, Myatra SN, Salluh JIF, Amare D, Azoulay E, Bellelli G, Csomos A, Fan E, et al. Worldwide survey of the \u201cassessing pain, both spontaneous awakening and breathing trials, choice of drugs, delirium monitoring\/management, early exercise\/mobility, and family empowerment\u201d (ABCDEF) Bundle. Crit Care Med. 2017;45(11):e1111\u201322.","journal-title":"Crit Care Med"},{"issue":"9","key":"4692_CR6","doi-asserted-by":"publisher","first-page":"e825","DOI":"10.1097\/CCM.0000000000003299","volume":"46","author":"JW Devlin","year":"2018","unstructured":"Devlin JW, Skrobik Y, Gelinas C, Needham DM, Slooter AJC, Pandharipande PP, Watson PL, Weinhouse GL, Nunnally ME, Rochwerg B, et al. Clinical practice guidelines for the prevention and management of pain, agitation\/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825\u201373.","journal-title":"Crit Care Med"},{"issue":"26","key":"4692_CR7","doi-asserted-by":"publisher","first-page":"2506","DOI":"10.1056\/NEJMoa1808217","volume":"379","author":"TD Girard","year":"2018","unstructured":"Girard TD, Exline MC, Carson SS, Hough CL, Rock P, Gong MN, Douglas IS, Malhotra A, Owens RL, Feinstein DJ, et al. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2018;379(26):2506\u201316.","journal-title":"N Engl J Med"},{"issue":"26","key":"4692_CR8","doi-asserted-by":"publisher","first-page":"2425","DOI":"10.1056\/NEJMoa2211868","volume":"387","author":"NC Andersen-Ranberg","year":"2022","unstructured":"Andersen-Ranberg NC, Poulsen LM, Perner A, Wetterslev J, Estrup S, Hastbacka J, Morgan M, Citerio G, Caballero J, Lange T, et al. Haloperidol for the treatment of delirium in ICU patients. N Engl J Med. 2022;387(26):2425\u201335.","journal-title":"N Engl J Med"},{"issue":"4","key":"4692_CR9","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1007\/s00134-023-07024-9","volume":"49","author":"NC Andersen-Ranberg","year":"2023","unstructured":"Andersen-Ranberg NC, Poulsen LM, Perner A, Hastbacka J, Morgan M, Citerio G, Collet MO, Weber SO, Andreasen AS, Bestle M, et al. Haloperidol versus placebo for the treatment of delirium in ICU patients: a pre-planned, secondary Bayesian analysis of the AID-ICU trial. Intensive Care Med. 2023;49(4):411\u201320.","journal-title":"Intensive Care Med"},{"issue":"26","key":"4692_CR10","doi-asserted-by":"publisher","first-page":"2464","DOI":"10.1056\/NEJMe2214417","volume":"387","author":"ER Marcantonio","year":"2022","unstructured":"Marcantonio ER. Haloperidol for treatment of ICU delirium: progress or setback? N Engl J Med. 2022;387(26):2464\u20135.","journal-title":"N Engl J Med"},{"issue":"9","key":"4692_CR11","doi-asserted-by":"publisher","first-page":"e036735","DOI":"10.1136\/bmjopen-2019-036735","volume":"10","author":"L Smit","year":"2020","unstructured":"Smit L, Trogrlic Z, Devlin JW, Osse RJ, Ponssen HH, Slooter AJC, Hunfeld NGM, Rietdijk WJR, Gommers D, van der Jagt M, et al. Efficacy of halopeRIdol to decrease the burden of delirium in adult critically ill patiEnts (EuRIDICE): study protocol for a prospective randomised multi-centre double-blind placebo-controlled clinical trial in the Netherlands. BMJ Open. 2020;10(9):e036735.","journal-title":"BMJ Open"},{"issue":"4","key":"4692_CR12","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1017\/S0033291700005742","volume":"19","author":"AF Jorm","year":"1989","unstructured":"Jorm AF, Jacomb PA. The informant questionnaire on cognitive decline in the elderly (IQCODE): socio-demographic correlates, reliability, validity and some norms. Psychol Med. 1989;19(4):1015\u201322.","journal-title":"Psychol Med"},{"issue":"10","key":"4692_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.2107138","volume":"166","author":"CN Sessler","year":"2002","unstructured":"Sessler CN, Gosnell MS, Grap MJ, Brophy GM, O\u2019Neal PV, Keane KA, Tesoro EP, Elswick RK. The Richmond agitation-sedation scale: validity and reliability in adult intensive care unit patients. Am J Respir Crit Care Med. 2002;166(10):1338\u201344.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"4692_CR14","doi-asserted-by":"publisher","first-page":"859","DOI":"10.1007\/s001340100909","volume":"27","author":"N Bergeron","year":"2001","unstructured":"Bergeron N, Dubois MJ, Dumont M, Dial S, Skrobik Y. Intensive care delirium screening checklist: evaluation of a new screening tool. Intensive Care Med. 2001;27(5):859\u201364.","journal-title":"Intensive Care Med"},{"issue":"21","key":"4692_CR15","doi-asserted-by":"publisher","first-page":"2703","DOI":"10.1001\/jama.286.21.2703","volume":"286","author":"EW Ely","year":"2001","unstructured":"Ely EW, Inouye SK, Bernard GR, Gordon S, Francis J, May L, Truman B, Speroff T, Gautam S, Margolin R, et al. Delirium in mechanically ventilated patients: validity and reliability of the confusion assessment method for the intensive care unit (CAM-ICU). JAMA. 2001;286(21):2703\u201310.","journal-title":"JAMA"},{"issue":"3","key":"4692_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/CCM.0000000000003596","volume":"47","author":"Z Trogrlic","year":"2019","unstructured":"Trogrlic Z, van der Jagt M, Lingsma H, Gommers D, Ponssen HH, Schoonderbeek JFJ, Schreiner F, Verbrugge SJ, Duran S, Bakker J, et al. Improved guideline adherence and reduced brain dysfunction after a multicenter multifaceted implementation of ICU delirium guidelines in 3930 patients. Crit Care Med. 2019;47(3):419\u201327.","journal-title":"Crit Care Med"},{"issue":"1","key":"4692_CR17","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1097\/CCM.0b013e3182783b72","volume":"41","author":"J Barr","year":"2013","unstructured":"Barr J, Fraser GL, Puntillo K, Ely EW, Gelinas C, Dasta JF, Davidson JE, Devlin JW, Kress JP, Joffe AM, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263\u2013306.","journal-title":"Crit Care Med"},{"issue":"7","key":"4692_CR18","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/S2213-2600(13)70166-8","volume":"1","author":"VJ Page","year":"2013","unstructured":"Page VJ, Ely EW, Gates S, Zhao XB, Alce T, Shintani A, Jackson J, Perkins GD, McAuley DF. Effect of intravenous haloperidol on the duration of delirium and coma in critically ill patients (Hope-ICU): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2013;1(7):515\u201323.","journal-title":"Lancet Respir Med"},{"issue":"7","key":"4692_CR19","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/S2213-2600(16)30138-2","volume":"4","author":"E Colantuoni","year":"2016","unstructured":"Colantuoni E, Dinglas VD, Ely EW, Hopkins RO, Needham DM. Statistical methods for evaluating delirium in the ICU. Lancet Respir Med. 2016;4(7):534\u20136.","journal-title":"Lancet Respir Med"},{"issue":"2","key":"4692_CR20","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/CCM.0b013e3181c58715","volume":"38","author":"TD Girard","year":"2010","unstructured":"Girard TD, Pandharipande PP, Carson SS, Schmidt GA, Wright PE, Canonico AE, Pun BT, Thompson JL, Shintani AK, Meltzer HY, et al. Feasibility, efficacy, and safety of antipsychotics for intensive care unit delirium: the MIND randomized, placebo-controlled trial. Crit Care Med. 2010;38(2):428\u201337.","journal-title":"Crit Care Med"},{"key":"4692_CR21","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","volume":"212","author":"GM Simpson","year":"1970","unstructured":"Simpson GM, Angus JW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl. 1970;212:11\u20139.","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"4692_CR22","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1186\/1741-7015-8-18","volume":"8","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. Group C: CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med. 2010;8:18.","journal-title":"BMC Med"},{"issue":"18","key":"4692_CR23","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1056\/NEJMc1901272","volume":"380","author":"RB Tenser","year":"2019","unstructured":"Tenser RB. Haloperidol and ziprasidone for treatment of delirium in critical illness. N Engl J Med. 2019;380(18):1778\u201380.","journal-title":"N Engl J Med"},{"issue":"5","key":"4692_CR24","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1097\/CCM.0000000000000863","volume":"43","author":"MA Pisani","year":"2015","unstructured":"Pisani MA, Araujo KL, Murphy TE. Association of cumulative dose of haloperidol with next-day delirium in older medical ICU patients. Crit Care Med. 2015;43(5):996\u20131002.","journal-title":"Crit Care Med"},{"issue":"9","key":"4692_CR25","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1097\/CCM.0000000000005028","volume":"49","author":"L Rose","year":"2021","unstructured":"Rose L, Burry L, Agar M, Campbell NL, Clarke M, Lee J, Marshall JC, Devlin JW, Blackwood B, Needham DM, et al. A core outcome set for research evaluating interventions to prevent and\/or treat delirium in critically ill adults: an international consensus study (Del-COrS). Crit Care Med. 2021;49(9):1535\u201346.","journal-title":"Crit Care Med"},{"issue":"2","key":"4692_CR26","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.ccc.2016.12.005","volume":"33","author":"A Marra","year":"2017","unstructured":"Marra A, Ely EW, Pandharipande PP, Patel MB. The ABCDEF bundle in critical care. Crit Care Clin. 2017;33(2):225\u201343.","journal-title":"Crit Care Clin"},{"issue":"3","key":"4692_CR27","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1164\/rccm.201101-0065OC","volume":"184","author":"MM van Eijk","year":"2011","unstructured":"van Eijk MM, van den Boogaard M, van Marum RJ, Benner P, Eikelenboom P, Honing ML, van der Hoven B, Horn J, Izaks GJ, Kalf A, et al. Routine use of the confusion assessment method for the intensive care unit a multicenter study. Am J Respir Crit Care Med. 2011;184(3):340\u20134.","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"4692_CR28","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1001\/jama.2018.0160","volume":"319","author":"M van den Boogaard","year":"2018","unstructured":"van den Boogaard M, Slooter AJC, Bruggemann RJM, Schoonhoven L, Beishuizen A, Vermeijden JW, Pretorius D, de Koning J, Simons KS, Dennesen PJW, et al. Effect of Haloperidol on survival among critically ill adults with a high risk of delirium: the REDUCE randomized clinical trial. JAMA. 2018;319(7):680\u201390.","journal-title":"JAMA"}],"container-title":["Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13054-023-04692-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13054-023-04692-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,30]],"date-time":"2023-10-30T16:05:27Z","timestamp":1698681927000},"score":1,"resource":{"primary":{"URL":"https:\/\/ccforum.biomedcentral.com\/articles\/10.1186\/s13054-023-04692-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,30]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["4692"],"URL":"https:\/\/doi.org\/10.1186\/s13054-023-04692-3","relation":{},"ISSN":["1364-8535"],"issn-type":[{"value":"1364-8535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,30]]},"assertion":[{"value":"6 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Medical Ethics Committees of all participating hospitals and has been published []. The study was conducted according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act (WMO) and other guidelines, regulations and Acts. Eligible patients or their legal representatives were asked for written informed consent as soon as possible after ICU admission to enable randomization as soon as possible after delirium was first diagnosed.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"413"}}